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This retrospective study reported that the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke, vascular disease, and sex) score is associated with longterm all-cause death, cardiac death, and stroke in patients who underwent percutaneous coronary intervention. The long-term all-cause mortality risk increased with every 1-point increase in the CHA 2 DS 2 -VASc score.
The CHA 2 DS 2 -VASc score, a guideline-based risk scoring system, is mainly used to determine the risk of thromboembolism in patients with nonvalvular atrial fibrillation.
1 Several studies also demonstrated that this score may be a predictor of in-hospital, short-, and long-term mortality in patients with acute coronary syndrome. [1] [2] [3] Moreover, a recent study reported that the CHA 2 DS 2 -VASc score can be used to estimate the prosthetic valve thrombosis risk in patient with a mechanical mitral valve. 4 The CHA 2 DS 2 -VASc score is a simple, inexpensive, and generalizable risk scoring system that is based on nonlaboratory parameters and can be easily applied by clinicians. These study 1 findings are valuable in terms of the applicability of the CHA 2 DS 2 -VASc score in daily clinical practice because the data presented herein may help optimize dual antiplatelet therapy (DAPT) according to the CHA 2 DS 2 -VASc score. Moreover, this study 1 highlights the need for further work to assess whether the treatment benefit or risk with high potency DAPT differs depending on the CHA 2 DS 2 -VASc score.
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